Drug Fix: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Citeline Podcasts
English - September 29, 2023 14:38 - 32 minutes - 19.8 MB - ★★★★★ - 24 ratingsBusiness News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug (:43), the impact of a government shutdown on the agency (10:00), and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations (22:58).
More On These Topics From The Pink Sheet
BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel: https://pink.citeline.com/PS148915/BrainStorms-NurOwn-Gets-Many-Many-Thumbs-Down-From-US-FDA-Panel
Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees: https://pink.citeline.com/PS148923/Preparing-For-A-Shutdown-US-FDA-To-Retain-81-Of-Workforce-Thanks-Mostly-To-User-Fees
Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions: https://pink.citeline.com/PS148917/Republican-Lawmaker-Takes-Unusual-Step-Of-Attacking-FDA-Salaries-Over-Abortion-Pill-Decisions
Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round: https://pink.citeline.com/PS148916/Imbruvica-Enbrel-Stelara-Offer-Best-Chance-Of-Savings-From-Medicare-Negotiation-In-First-Round